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ABSTRACT
Background: The aims of the present report were to estimate the prevalence of congenital anomalies (CAs) among infants in
Japan using data from the Japan Environment and Children’s Study (JECS) and to evaluate the validity of CA classification
within JECS.
Methods: Data on CAs were collected at delivery and at age 1 month from the medical records of 101,825 infants at 15 regional
centers. The analyses focused on 61 CAs, selected on the basis of reported associations with environmental exposure.
Prevalence per 10,000 pregnancies (including miscarriages, stillbirths, and live births) was stratified according to four reporting
patterns (at delivery, at age 1 month, at either, and at both). To evaluate the accuracy of observed CA prevalence, the medical
records of 179 cases from a single JECS regional center underwent independent, retrospective re-evaluation.
Results: The prevalence of major CAs in four reporting patterns (at delivery, at age 1 month, at either, and at both) was 2.4, 2.6,
3.5, and 1.4 for myelomeningocele=spina bifida; 4.3, 4.2, 5.3, and 3.2 for cleft palate; 18.1, 17.4, 19.5, and 15.1 for cleft lip with
or without cleft palate; 73.4, 100.3, 120.8, and 52.8 for congenital heart disease; and 10.5, 14.1, 15.0, and 9.6 for Down’s
syndrome, respectively. In the subsample re-evaluation, CA diagnoses were confirmed for 92.7%, 93.3%, 90.5%, and 97.8% of
cases in the four reporting patterns (at delivery, at age 1 month, at either, and at both), respectively.
Conclusions: The present report generated reliable data concerning the prevalence of major CAs in JECS.
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INTRODUCTION
Congenital anomalies (CAs) are an important cause of not only
infant and childhood deaths but also chronic illness and lifelong
disability.1 To date, approximately 50% of CAs have been linked
to a specific cause, genetic, socioeconomic and demographic,
environmental, infectious, and maternal nutritional risk factors
are known at present.2 Environmental toxicants that are known
to cause several CAs are one of the risk factors that can be
minimized by appropriate standards and regulations. The reported
risk factors for congenital heart disease include prenatal exposure
to pesticides, organic solvents, and air pollution.3,4 Exposure to
some endocrine disrupters has been linked to cryptorchidism and
hypospadias.5 Pesticide exposure is associated with urinary
malformations.6 However, evidence for many of these relation-
ships is still limited.
The Japan Environment and Children’s Study (JECS) is a
nationwide prospective birth cohort study conducted by the
Ministry of the Environment of Japan. The aims of JECS are to
identify environmental factors, in particular chemical substances,
with a detrimental impact on child health and development, and
to facilitate improved environmental risk management system.
CAs are one of the priority health outcomes of JECS. However,
the collection of CA data in JECS is hampered by the fact that, to
date, no population-based CA registration or surveillance system
has been established in Japan. At its 15 regional centers, JECS
investigators therefore collect data on CAs from the medical
records of infants at delivery and at 1 month of age.
The aims of the present report were to estimate the prevalence
of CAs among infants from Japan using data from the JECS
cohort and to evaluate the validity of CA classification within
JECS.
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Recruitment of women in the first trimester of pregnancy took
place between January 2011 and March 2014 at the 15 JECS
regional centers. The respective offspring will undergo follow-
up until the age of 13 years. JECS protocols are described in
detail elsewhere.7,8 During the JECS recruitment period, a total
of 104,102 infants were enrolled through hospitals or local
government offices. In the event of miscarriage, medical
termination of pregnancy, stillbirth, or neonatal mortality, the
respective regional center collected and recorded the necessary
data prior to termination of JECS participation. All types of
obstetric facilities (perinatal medical centers, maternity hospitals,
and maternity homes) cooperated with JECS to increase the
participation rate. No data concerning the participation rate across
the entire JECS recruitment period were collected, since the
recruitment area was expanded in 2012 and recruitment during
2011 and 2014 was restricted to a period of 3 months. However,
in 2013, when recruitment had largely stabilized, JECS collected
data on 45% of all total live births across its 15 geographical
recruitment regions.7
All JECS procedures adhere to the Ethical Guidelines for
Epidemiological Research of the Japan Ministry of Health,
Labour, and Welfare. JECS protocols were reviewed and
approved by the Institutional Review Board of the Ministry of
the Environment, and by the ethics committees of all participating
institutions. Written informed consent was obtained from all
pregnant women prior to inclusion.
Cohort used for the investigation of CA prevalence
For the purpose of the present report, the following JECS cases
were excluded: (i) cases in which no data at the CA reporting
time-points were available (n = 2,277), and ii) cases in which
pregnancy outcome was unknown (n = 38).
Some participants were withdrawn from the study after the
completion of data collection at delivery due to miscarriage
(n = 1,340) and stillbirth (n = 291). Follow-up of these
participants was terminated following the collection of data at
delivery. In 705 participants, data were available at the delivery
time-point but not at 1 month. In the case of 44 participants, data
were available at the 1 month time-point but not at delivery.
In each case, the reason for this was undocumented.
Collection of congenital anomaly data
The present analyses focused on a list of 61 CAs (Table 1).
This represents a modified version of the list used in the
Hokkaido Study on Environment and Children’s Health. The
latter comprised 55 CAs, which were selected as possible markers
of environmental exposure.9
CA data were collected by transcribing information entered
in the infants’ medical records at delivery and at 1 month of
age onto JECS transcription forms. This information included
the respective 10th revision of the International Statistical
Classification of Diseases and Related Health Problems (ICD)
code (Table 1), and the terminology used to denote the CA in the
medical records. In each case, this process was completed by a
physician, a midwife, a nurse, or a trained research coordinator.
Each CA was listed in the transcription form in a separate box.
If any of the 61 CAs of interest were observed, a tick was entered
into the corresponding box.
Categorization of anomalies described in the com-
ment section
When CAs not listed in Table 1 were found or suspected in
medical records, the information was transcribed into a comment
section (ie, uncategorized CAs), to reduce the number of cases
overlooked by the person making the transcription.
In total, 13,144 uncategorized CAs were recorded in the
comment sections. Two pediatricians (H.M. and Y.Y.) independ-
ently evaluated the respective comments and categorized the
described anomalies as specific CAs. If uncategorized CA
information containing misspellings, unexplained abbreviations,
or any ambiguity were detected, these were corrected by the
pediatricians prior to categorization. For the purposes of the
present analyses, suspected CAs were assessed using the
comment sections of the transcription forms only. The respective
medical records were not consulted. Suspected CAs still awaiting
formal diagnosis were not categorized as CAs for the purposes of
the present analyses. In cases of uncertainty, the two pediatricians
assigned a consensus diagnosis.
For the valuation of entries in the comments section, 31 CAs
that were easily detected at delivery and that generally required
prompt medical attention after delivery were selected from the
list of 61 CAs of interest. The 31 selected CAs comprised
anencephaly, encephalocele, hydrocephaly, holoprosencephaly,
ablepharon, microphthalmia=anophthalmia, congenital cataract,
cleft lip (CL), cleft palate (CP), cleft lip and palate (CLP),
facial cleft, diaphragmatic hernia, congenital heart disease,
omphalocele, gastroschisis, esophageal atresia with or without
fistula, duodenal atresia=stenosis, intestinal atresia=stenosis,
anorectal atresia=stenosis, hypospadias, undescended testis=
cryptorchidism, polydactyly of the fingers, syndactyly of the
fingers, cleft hand, polydactyly of the toes, syndactyly of the
toes, cleft foot, myelomeningocele=spina bifida, Down syndrome,
Trisomy 18, and Trisomy 13. Through this process, a total of
755 uncategorized CAs (5.74%) were categorized as CAs.
Covariates
Data were also collected on mother’s age at delivery, regional
center, singleton=multiple pregnancy, and pregnancy outcomes
(live birth, spontaneous abortion, medical termination of
pregnancy, and stillbirth). Stillbirth was defined as the occurrence
of fetal death at >21 weeks gestation.
Analysis of CA prevalence
Data collected at delivery only were stratified according to four
pregnancy outcomes: 1) spontaneous abortion, 2) medical
termination of pregnancy, 3) stillbirth, and 4) live birth. All
cases in which CAs had been recorded at the 1 month time-point
only were classified as live births.
In a first step, data collected both at delivery and at 1 month
were stratified according to the four possible CA reporting
patterns: 1) CA recorded at delivery time-point only, 2) CA
recorded at 1 month time-point only, 3) CA recorded either at
delivery or at 1 month, and 4) CA recorded at both delivery
and the 1 month time-point. For each of these four categories,
the type, number, and percentage of CAs are shown in Table 1.
A high CA prevalence was observed in the following two
data collection patterns: 1) data collected at delivery only, and
2) data collected at 1 month of age only. The number of CAs
recorded in these two data collection patterns are shown in
Table 2.
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Table 1. Number and percentage of the 61 congenital anomalies of interest according to reporting and data collection patterns
ICD-10 codec





















N 1,010 330 291 705 44 99445
Anencephaly Q00 3 0.297 12 3.636 0 0.000 1 0.142 0 0.000 12 0.012 5 0.005 16 0.016 1 0.001
Encephalocele Q01 1 0.099 1 0.303 0 0.000 1 0.142 0 0.000 10 0.010 12 0.012 19 0.019 3 0.003
Microcephaly Q02 0 0.000 1 0.303 0 0.000 0 0.000 0 0.000 10 0.010 28 0.028 37 0.037 1 0.001
Hydrocephaly Q03 1 0.099 2 0.606 2 0.687 3 0.426 1 2.273 34 0.034 63 0.063 80 0.080 17 0.017
Craniotabes P96.3 0 0.000 0 0.000 0 0.000 0 0.000 0 0.000 35 0.035 35 0.035 69 0.069 1 0.001
Holoprosencephaly Q04.2 2 0.198 7 2.121 1 0.344 1 0.142 0 0.000 12 0.012 27 0.027 32 0.032 7 0.007
Agenesis of corpus callosum Q04.0 0 0.000 2 0.606 1 0.344 0 0.000 1 2.273 13 0.013 15 0.015 20 0.020 8 0.008
Ablepharon Q10.3 0 0.000 0 0.000 0 0.000 0 0.000 0 0.000 5 0.005 8 0.008 13 0.013 0 0.000
Anophthalmos=microphthalmos Q11.0–Q11.2 0 0.000 0 0.000 0 0.000 1 0.142 0 0.000 15 0.015 11 0.011 21 0.021 5 0.005
Congenital cataract Q12.0 0 0.000 0 0.000 0 0.000 0 0.000 0 0.000 17 0.017 13 0.013 30 0.030 0 0.000
Microtia Q17.2 0 0.000 0 0.000 0 0.000 0 0.000 0 0.000 19 0.019 24 0.024 40 0.040 3 0.003
Congenital aural atresia Q16.1 1 0.099 0 0.000 0 0.000 0 0.000 0 0.000 32 0.032 16 0.016 39 0.039 9 0.009
Cryptotia Q17.8 0 0.000 0 0.000 0 0.000 0 0.000 0 0.000 19 0.019 19 0.019 33 0.033 5 0.005
Low set ears Q17.4 3 0.297 2 0.606 3 1.031 8 1.135 0 0.000 54 0.054 36 0.036 78 0.078 12 0.012
Cleft lip Q36 1 0.099 3 0.909 1 0.344 1 0.142 0 0.000 63 0.063 62 0.062 76 0.076 49 0.049
Cleft palate Q35 1 0.099 0 0.000 0 0.000 1 0.142 0 0.000 42 0.042 41 0.041 52 0.052 31 0.031
Cleft lip and palate Q37.0–Q37.5 1 0.099 0 0.000 2 0.687 5 0.709 0 0.000 107 0.108 101 0.102 117 0.118 91 0.092
not classified as cleft lip,
cleft palate or cleft lip and palatea
13 0.013
Facial cleft Q37.8 Q37.9 0 0.000 0 0.000 0 0.000 0 0.000 0 0.000 7 0.007 4 0.004 9 0.009 2 0.002
Natal teeth K00.6 0 0.000 0 0.000 0 0.000 0 0.000 0 0.000 46 0.046 32 0.032 64 0.064 14 0.014
Diaphragmatic hernia Q79.0 0 0.000 0 0.000 1 0.344 5 0.709 0 0.000 28 0.028 22 0.022 37 0.037 13 0.013
Intralobar sequestration Q33.2 0 0.000 0 0.000 0 0.000 0 0.000 0 0.000 1 0.001 4 0.004 5 0.005 0 0.000
Congenital cystic adenomatoid
malformation
Q33.0 0 0.000 0 0.000 0 0.000 1 0.142 0 0.000 9 0.009 11 0.011 14 0.014 6 0.006
Pulmonary hypoplasia Q33.6 0 0.000 0 0.000 1 0.344 6 0.851 0 0.000 17 0.017 19 0.019 27 0.027 9 0.009




0 0.000 0 0.000 0 0.000 2 0.284 0 0.000 80 0.080 48 0.048 104 0.105 24 0.024
Omphalocele Q79.2 2 0.198 4 1.212 0 0.000 1 0.142 0 0.000 36 0.036 265 0.266 282 0.284 19 0.019
Gastroschisis Q79.3 4 0.396 4 1.212 1 0.344 2 0.284 0 0.000 9 0.009 5 0.005 10 0.010 4 0.004
Esophageal atresia with
or without fistula
Q39.0 Q39.1 0 0.000 0 0.000 1 0.344 4 0.567 0 0.000 14 0.014 14 0.014 18 0.018 10 0.010
Duodenal atresia=stenosis Q41.0 0 0.000 0 0.000 0 0.000 0 0.000 0 0.000 17 0.017 13 0.013 19 0.019 11 0.011
Intestinal atresia=stenosis Q41.1–Q41.9 0 0.000 0 0.000 0 0.000 0 0.000 0 0.000 16 0.016 10 0.010 18 0.018 8 0.008
Anorectal atresia=stenosis Q42.0–Q42.9 0 0.000 0 0.000 0 0.000 1 0.142 0 0.000 38 0.038 36 0.036 45 0.045 29 0.029
Inguinal hernia K40.2 0 0.000 0 0.000 0 0.000 0 0.000 0 0.000 29 0.029 98 0.099 113 0.114 14 0.014
Congenital hydronephrosis Q62.0 0 0.000 1 0.303 0 0.000 0 0.000 0 0.000 145 0.146 163 0.164 216 0.217 92 0.093
Cystic kidney Q61 0 0.000 2 0.606 0 0.000 4 0.567 0 0.000 23 0.023 22 0.022 31 0.031 14 0.014
Renal agenesis Q60.2 2 0.198 1 0.303 2 0.687 0 0.000 0 0.000 5 0.005 6 0.006 8 0.008 3 0.003
Hypospadias Q54 0 0.000 0 0.000 0 0.000 1 0.142 0 0.000 46 0.046 50 0.050 65 0.065 31 0.031
Undescended testis=cryptorchidism Q53 0 0.000 0 0.000 0 0.000 2 0.284 0 0.000 213 0.214 161 0.162 306 0.308 68 0.068
Bladder exstrophy Q64.1 0 0.000 0 0.000 0 0.000 0 0.000 0 0.000 3 0.003 2 0.002 3 0.003 2 0.002
Enlarged clitoris N90.8 0 0.000 0 0.000 0 0.000 0 0.000 0 0.000 6 0.006 6 0.006 12 0.012 0 0.000
Abnormal Vaginal Opening Q52.4 1 0.099 0 0.000 0 0.000 0 0.000 0 0.000 1 0.001 1 0.001 2 0.002 0 0.000
Indeterminate sex Q56 1 0.099 0 0.000 0 0.000 1 0.142 0 0.000 6 0.006 2 0.002 7 0.007 1 0.001
Polydactyly of fingers Q69 Q70.4 0 0.000 3 0.909 2 0.687 0 0.000 0 0.000 98 0.099 82 0.082 106 0.107 74 0.074
Syndactyly of fingers Q70 0 0.000 2 0.606 0 0.000 4 0.567 0 0.000 34 0.034 25 0.025 41 0.041 18 0.018
Cleft hand Q71.6 0 0.000 0 0.000 0 0.000 0 0.000 0 0.000 4 0.004 4 0.004 5 0.005 3 0.003
Polydactyly of toes Q69 Q70.4 0 0.000 0 0.000 0 0.000 1 0.142 0 0.000 67 0.067 57 0.057 88 0.088 36 0.036
Syndactyly of toes Q70 0 0.000 0 0.000 0 0.000 3 0.426 0 0.000 70 0.070 73 0.073 101 0.102 42 0.042
Cleft foot Q72.7 0 0.000 0 0.000 0 0.000 0 0.000 0 0.000 6 0.006 4 0.004 7 0.007 3 0.003
Hemangioma Q82.5 0 0.000 0 0.000 0 0.000 1 0.142 0 0.000 186 0.187 633 0.637 756 0.760 63 0.063
Epidermolysis bullosa Q82.3 0 0.000 0 0.000 0 0.000 1 0.142 0 0.000 9 0.009 7 0.007 14 0.014 2 0.002
Myelomeningocele=Spina bifida Q05 0 0.000 1 0.303 1 0.344 1 0.142 0 0.000 21 0.021 23 0.023 33 0.033 11 0.011
Down syndrome Q90 0 0.000 9 2.727 0 0.000 6 0.851 0 0.000 92 0.093 129 0.130 138 0.139 83 0.083
Trisomy 18 Q91.0–Q91.3 0 0.000 5 1.515 7 2.405 6 0.851 0 0.000 19 0.019 23 0.023 27 0.027 15 0.015
Trisomy 13 Q91.4–Q91.7 2 0.198 0 0.000 1 0.344 0 0.000 0 0.000 3 0.003 5 0.005 5 0.005 3 0.003
Turner syndrome Q96 1 0.099 1 0.303 0 0.000 0 0.000 0 0.000 2 0.002 3 0.003 4 0.004 1 0.001
Thanatophoric dysplasia Q77.1 0 0.000 2 0.606 0 0.000 1 0.142 0 0.000 2 0.002 1 0.001 3 0.003 0 0.000
Acrodysostosis, not specificied Q77.4 0 0.000 0 0.000 1 0.344 0 0.000 0 0.000 4 0.004 3 0.003 5 0.005 2 0.002
Developmental dysplasia of the hipb Q65.0–Q65.6 0 0.000 14 0.014 14 0.014
Congenital multiple arthrogryposis Q74.3 0 0.000 0 0.000 0 0.000 0 0.000 0 0.000 5 0.005 4 0.004 8 0.008 1 0.001
Floppy infant P94.2 0 0.000 0 0.000 0 0.000 0 0.000 0 0.000 11 0.011 8 0.008 16 0.016 3 0.003
Conjoined twins Q89.4 1 0.099 1 0.303 0 0.000 0 0.000 0 0.000 0 0.000 2 0.002 2 0.002 0 0.000
Amniotic band constriction Q79.8 3 0.297 4 1.212 0 0.000 0 0.000 0 0.000 2 0.002 2 0.002 2 0.002 2 0.002
ICD-10, International Statistical Classification of Diseases and Related Health Problems, 10th revision.
Each congenital anomaly is listed with its number of cases and percentage per data collection patterns.
a
“not classified as cleft lip, cleft palate or cleft lip and palate” included the different reporting case from at delivery and at one month of age within cleft lip, cleft
palate or cleft lip and palate.
bDevelopmental dysplasia of the hip was included in the transcription form at 1 month of age only.
cTranscriptions of both the ICD-10 code and congenital anomaly name in medical records were collected at the data collection phase.
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In a second step, data from the two data collection patterns
showing a high prevalence of CAs (delivery only and 1 month of
age only) were stratified for the four CA reporting patterns: 1) CA
reporting at delivery data collection only (D-DELIVERY), 2) CA
reporting at 1 month data collection only (D-1M), 3) CA
reporting either at delivery or at 1 month data collection (D-OR),
and 4) CA reporting both at delivery and at 1 month data
collection (D-AND). For each of the four reporting patterns, the
prevalence of the CA per 10,000 pregnancies was then calculated.
Categorization of CP, CL, and CLP
In accordance with other epidemiological studies, CL and CLP
were re-categorized as ‘cleft lip with or without cleft palate’ (CL=
P). In eight cases, CLP was reported at one time and CL at
another time. In four cases, CL and CLP were reported at the each
time. In one case, CP and CL were reported at the each time.
Therefore, 13 cases were recorded as “not classified as CL, CP, or
CLP” in Table 1. Of these, eight cases were categorized as CL=P
for the purposes of the present analyses.
Independent evaluation of congenital anomaly data
accuracy
For almost all CAs, a difference in prevalence was observed
between the four reporting categories. From December 2016
through March 2017, the accuracy of data collection was
therefore assessed via direct, expert re-evaluation of transcription
form content. For this purpose, three physicians (two pedia-
tricians and one physician) worked with the Kochi regional
center, and each hospital pediatrician and maternal clinic
gynecologist independently performed a retrospective review
of the transcription forms and respective medical and health
insurance records of 179 CA infants from the Kochi regional
center. In total, the Kochi regional center enrolled 7,140 pregnant
women. The target anomalies for this re-evaluation process were
the 31 easily detectable, major CAs assessed in the analysis of
comment section data. The 179 infants were all cases with the
target anomalies.
In cases in which information on the CA could not be located
in the medical or insurance records, the physicians categorized
Table 2. Number and prevalence per 10,000 pregnancies of the 61 congenital anomalies of interest according to reporting pattern
Congenital anomaly
Total number Prevalence per 10,000 pregnancies
D-DELIVERYa D-1Mb D-ORc D-ANDd D-DELIVERYa D-1Mb D-ORc D-ANDd
Total number 101,825 101,825 101,825 101,825
Major anomalies 1,959 2,437 3,041 1,290 192.4 239.3 298.6 126.7
Central nervous system 174 228 313 84 17.1 22.4 30.7 8.2
Neural tube defect 65 61 88 37 6.4 6.0 8.6 3.6
Anencephaly 28 21 32 17 2.7 2.1 3.1 1.7
Encephalocele 13 15 22 6 1.3 1.5 2.2 0.6
Myelomeningocele=Spina bifida 24 26 36 14 2.4 2.6 3.5 1.4
Hydrocephaly 43 72 89 26 4.2 7.1 8.7 2.6
Microcephaly 11 29 38 2 1.1 2.8 3.7 0.2
Holoprosencephaly 23 38 43 18 2.3 3.7 4.2 1.8
Craniotabes 35 35 69 1 3.4 3.4 6.8 0.1
Agenesis of corpus callosum 17 19 24 12 1.7 1.9 2.4 1.2
Eye 33 24 50 6 3.2 2.4 4.9 0.6
Anophthalmos=microphthalmos 16 12 22 6 1.6 1.2 2.2 0.6
Congenital cataract 17 13 30 0 1.7 1.3 2.9 0.0
Ear 51 35 71 15 5.0 3.4 7.0 1.5
Congenital aural atresia 33 17 40 10 3.2 1.7 3.9 1.0
Cryptotia 19 19 33 5 1.9 1.9 3.2 0.5
Oro-facial cleft 232 223 254 188 22.8 21.9 24.9 18.5
Cleft palate 44 43 54 33 4.3 4.2 5.3 3.2
Cleft lip with or without palatee 184 177 199 154 18.1 17.4 19.5 15.1
Facial cleft 7 4 9 2 0.7 0.4 0.9 0.2
Respiratory system 35 40 52 23 3.4 3.9 5.1 2.3
Intralobar sequestration 1 4 5 0 0.1 0.4 0.5 0.0
Congenital cystic adenomatoid malformation 10 12 15 7 1.0 1.2 1.5 0.7
Pulmonary hypoplasia 24 26 34 16 2.4 2.6 3.3 1.6
Congenital heart disease 747 1,021 1,230 538 73.4 100.3 120.8 52.8
Cardiac arrhythmia 82 50 106 26 8.1 4.9 10.4 2.6
Abdominal wall defects 61 286 307 40 6.0 28.1 30.1 3.9
Omphalocele 43 272 289 26 4.2 26.7 28.4 2.6
Gastroschisis 20 16 21 15 2.0 1.6 2.1 1.5
Digestive system 121 100 140 79 11.9 9.8 13.7 7.8
Esophageal atresia with or without fistula 19 19 23 15 1.9 1.9 2.3 1.5
Duodenal atresia=stenosis 17 13 19 11 1.7 1.3 1.9 1.1
Intestinal atresia=stenosis 16 10 18 8 1.6 1.0 1.8 0.8
Anorectal atresia=stenosis 39 37 46 30 3.8 3.6 4.5 2.9
Diaphragmatic hernia 34 28 43 19 3.3 2.7 4.2 1.9
Continued on next page:
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the transcription form as erroneous and added a comment to the
data. The re-evaluation results were categorized as: 1) confirmed
or 2) not confirmed. The number and percentage of CAs in each
category were then calculated according to the data reporting
pattern.
Statistical analysis
All analyses were performed using SAS version 9.4 (SAS
Institute, Cary, NC, USA). Binary variables are shown as the
number of persons and percentages (%) by category. Incidence is
the total number of each CA case in the data reporting pattern.
CA cases categorized according to organ were counted if
any subordinate CAs were reported. In this previous report,
prevalence estimated per 10,000 pregnancies (including sponta-
neous abortion, medical termination of pregnancy, stillbirth, and
live birth) was stratified according to the reporting pattern. All
prevalence included any type of data collection.
RESULTS
The final analyses included data from a total of 101,825 infants.
Figure 1 shows the Venn diagram of the three data collection
patterns: (i) both at delivery and at 1 month of age (n = 99,445
infants), (ii) at delivery only (n = 2,336 infants), and (iii) at 1
Continued:
Congenital anomaly
Total number Prevalence per 10,000 pregnancies
D-DELIVERYa D-1Mb D-ORc D-ANDd D-DELIVERYa D-1Mb D-ORc D-ANDd
Urinary system 186 201 265 122 18.3 19.7 26.0 12.0
Congenital hydronephrosis 146 164 217 93 14.3 16.1 21.3 9.1
Cystic kidney 29 28 37 20 2.8 2.7 3.6 2.0
Renal agenesis 10 11 13 8 1.0 1.1 1.3 0.8
Bladder exstrophy 3 2 3 2 0.3 0.2 0.3 0.2
Genital system 53 55 73 35 5.2 5.4 7.2 3.4
Hypospadias 47 51 66 32 4.6 5.0 6.5 3.1
Indeterminate sex 8 4 9 3 0.8 0.4 0.9 0.3
Limb 232 212 273 158 22.8 20.8 26.8 15.5
Polydactyly 162 137 184 111 15.9 13.5 18.1 10.9
Polydactyly of fingers 103 87 111 79 10.1 8.5 10.9 7.8
Polydactyly of toes 68 58 89 37 6.7 5.7 8.7 3.6
Syndactyly 104 99 135 64 10.2 9.7 13.3 6.3
Syndactyly of fingers 40 31 47 24 3.9 3.0 4.6 2.4
Syndactyly of toes 73 76 104 45 7.2 7.5 10.2 4.4
Cleft hand or foot 9 6 10 5 0.9 0.6 1.0 0.5
Cleft hand 4 4 5 3 0.4 0.4 0.5 0.3
Cleft foot 6 4 7 3 0.6 0.4 0.7 0.3
Skeletal dysplasia 10 8 12 6 1.0 0.8 1.2 0.6
Thanatophoric dysplasia 5 4 6 3 0.5 0.4 0.6 0.3
Acrodysostosis, not specificied 5 4 6 3 0.5 0.4 0.6 0.3
Chromosomal 154 195 208 140 15.1 19.2 20.4 13.7
Down syndrome 107 144 153 98 10.5 14.1 15.0 9.6
Trisomy 18 37 41 45 33 3.6 4.0 4.4 3.2
Trisomy 13 6 8 8 6 0.6 0.8 0.8 0.6
Turner syndrome 4 5 6 3 0.4 0.5 0.6 0.3
Ablepharon 5 8 13 0 0.5 0.8 1.3 0.0
Epidermolysis bullosa 10 8 15 3 1.0 0.8 1.5 0.3
Developmental dysplasia of the hipf — 14 14 — — 1.4 1.4 —
Congenital multiple arthrogryposis 5 4 8 1 0.5 0.4 0.8 0.1
Floppy infant 11 8 16 3 1.1 0.8 1.6 0.3
Conjoined twins 2 4 4 2 0.2 0.4 0.4 0.2
Amniotic band constriction 9 9 9 9 0.9 0.9 0.9 0.9
Minor anomalies
Microtia 19 24 40 3 1.9 2.4 3.9 0.3
Low set ears 70 52 94 28 6.9 5.1 9.2 2.7
Natal teeth 46 32 64 14 4.5 3.1 6.3 1.4
Inguinal hernia 29 98 113 14 2.8 9.6 11.1 1.4
Undescending testis=cryptorchidism 215 163 308 70 21.1 16.0 30.2 6.9
Enlarged clitoris 6 6 12 0 0.6 0.6 1.2 0.0
Abnormal Vaginal Opening 2 2 3 1 0.2 0.2 0.3 0.1
Hemangioma 187 634 757 64 18.4 62.3 74.3 6.3
aD-DELIVERY includes congenital anomalies reported only at the birth data collection phase.
bD-1M includes congenital anomalies reported only at one month data collection.
cD-OR includes congenital anomalies reported either at birth or at one month data collection.
dD-AND includes congenital anomalies reported both at birth and at one month data collection, only at birth, and only at one month data collection.
eCL and CLP were re-categorized as ‘cleft lip with or without cleft palate’ (CL=P).
fDevelopmental dysplasia of the hip was only collected at one month data collection.
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month of age only (n = 44 infants). Pregnancy outcomes in the
“at delivery only group” comprised 291 stillbirths (0.29%), 1,010
spontaneous abortions (0.99%), 330 medical terminations of
pregnancies (0.32%), and 705 livebirths (0.69%). The numbers of
infants at each regional center, stratified according to maternal
age at delivery, are shown in eTable 1.
Table 1 shows the number and percentages of 61 CAs of
interest, stratified according to reporting pattern. In the
spontaneous abortion, medical termination of pregnancy, and
stillbirth groups, several major CAs were reported. In particular,
nine Down syndrome cases (2.73%) were found in the medical
termination of pregnancy group, while six Down syndrome cases
(0.85%) were reported in the live birth group.
Among live births in the group with at delivery data only,
major CAs were reported in 705 infants. Two major CAs were
also reported in the group with 1 month data only. Among data
collected both at delivery and at 1 month, the total number of
each CA varied according to data reporting pattern, with the
exception of amniotic band constriction. The number of
omphalocele cases was substantially higher at 1 month than at
delivery.
Prevalence of each congenital anomaly
Table 2 summarizes the number and prevalence per 10,000
pregnancies of the 61 CAs of interest, stratified according to
reporting pattern. The prevalence of major anomalies in each
reporting pattern ranged from 126.7 to 298.6 per 10,000
pregnancies. D-OR had the highest and D-AND the lowest
prevalence. Compared with D-DELIVERY and D-1M, the
prevalence of almost all major CAs was similar or higher in D-
1M. Concerning prevalence according to organ, congenital heart
disease showed the highest prevalence, followed by ∼20 cases
per 10,000 pregnancies for limb, urinary system, oro-facial cleft,
and central nervous system. By contrast, the prevalence of eye,
ear, respiratory system, genital system, and skeletal dysplasia
CAs was low, at less than 10 per 10,000 pregnancies. The
prevalence of digestive system and chromosomal CAs was 10 per
10,000 pregnancies. There was a difference in the number of
abdominal wall defects between D-DELIVERY (6.0) and D-1M
(28.1).
Independent evaluation of congenital anomaly data
accuracy
Of the 179 CA cases that underwent re-evaluation, one was found
to have been miscoded in the transcription form, eight were
withdrawn from the study after delivery, and two were not
recorded due to the hospital’s refusal to disclose the information.
Details of the remaining 168 cases are shown in Table 3. In the
D-DELIVERY group, 115 CAs (92.7%) were confirmed and nine
(7.3%) were not confirmed. In the D-1M group, 126 CAs (93.3%)
were confirmed and nine (6.7%) were not confirmed. In the D-OR
group, 152 CAs (90.5%) were confirmed and 16 (9.5%) were not
confirmed. In the D-AND group, 89 CAs (97.8%) were confirmed
and two (2.2%) were not confirmed. For 16 cases, no description
Data collection 
at both birth 
and at 1 month of age
n=99,445
Data collection 
at 1 month of age only
n=44





live birth n=705  
Total participants 
n=101,825 Data collection 
at 1 month of age
n=99,489
Data collection at birth
n=101,781
Figure 1. Venn diagram of congenital anomaly data collected from information entered in the medical records at delivery and at
1 month of age.
Table 3. Number and percentage of congenital anomalies in the
Kochi subsample according to reporting pattern
D-DELIVERYa D-1Mb D-ORc D-ANDd
Medical records
Confirmed 115 92.7% 126 93.3% 152 90.5% 89 97.8%
Not confirmed 9 7.3% 9 6.7% 16 9.5% 2 2.2%
Total 124 100% 135 100% 168 100% 91 100%
Each medical record status is shown with number and percentage by
category.
aD-DELIVERY includes congenital anomalies reported only at delivery data
collection.
bD-1M includes congenital anomalies reported only at 1 month data
collection.
cD-OR includes congenital anomalies reported either at delivery or at 1
month data collection.
dD-AND includes congenital anomalies reported both at delivery and at 1
month data collection, only at delivery, and only at 1 month data collection.
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of the CA was found in the respective medical or and health
insurance records. The 16 suspected CAs comprised diaphrag-
matic hernia (n = 5), congenital heart disease (n = 3), congenital
hydronephrosis (n = 2), duodenal atresia=stenosis (n = 1), in-
testinal atresia=stenosis (n = 1), myelomeningocele=spina bifida
(n = 1), omphalocele (n = 1), polydactyly of the fingers (n = 1),
and undescended testis=cryptorchidism (n = 1). Of the five cases
of unreported diaphragmatic hernia, four were in the D-
DELIVERY and one was in the D-1M. There were no other
CAs without descriptions in the medical and insurance records
in the non-confirmed 16 cases. eTable 2 shows the number and
proportion of CAs for which confirmation in accordance with
the ICD-10 code entered in the respective medical records was
achieved.
DISCUSSION
Using data from the JECS nationwide prospective birth cohort
study, the present report analyzed: (i) data collection patterns, and
(ii) the number and prevalence of 61 CAs of interest, which were
stratified according to the pattern of data reporting. A high CA
prevalence was observed in data collected at a single time-point
(at delivery only or at 1 month of age only). In addition, differing
numbers of CAs were observed between the different data
reporting patterns. To investigate this, an independent evaluation
was performed of the accuracy of the transcribing of data from
medical records to the study transcription forms across each of the
data reporting patterns. This was performed using a subsample
from the Kochi regional JECS center. In this evaluation,
confirmation in the medical=insurance records was achieved for
90.5% of CAs in the D-OR and 97.8% of CAs in the D-AND.
We also reported differences in prevalence according to organ.
In the present report, at least 90.5% of the CAs reported in
the transcription forms were confirmed after re-evaluation of
the corresponding medical and insurance records. Transcription
errors were mainly due to misclassifications that caused a bias
toward the null value when the misclassification rate was equal
between the two compared groups.9 In the JECS protocol, the
misclassification was equal for exposures to environmental
toxicants because the assessors were blinded to the exposure
measurements. Rui et al investigated the impact of misclassifi-
cation and measurement errors using a simulation study approach.
In their study, when the prevalence of one disease was low (3.2%)
and the effect size was small (0.3), a power of 15.1% was
observed between no misclassification and high sensitivity and
specificity scenario (sensitivity 0.84 and specificity 0.96) with
a small amount of covariate measurement error.10 By contrast,
the JECS sample size was calculated with sufficient power.
For instance, to test a hypothesis concerning a disorder with a
prevalence of 0.1%, such as Down syndrome, with a relative
risk of 2.0 and an alpha error of 0.05, and using a cohort in
which the proportion of individuals with a high level of exposure
to the chemical substance of interest is 25%, a sample size of
64,536 participants is required to provide a statistical power of
80%.11 The JECS cohort exceeds this sample size by 101,825.
Thus, even if around 15% of the statistical power was lost, the
JECS CA data still retained sufficient power to address the study
hypotheses. Thus, since data accuracy in the Kochi report had
a sensitivity of >0.84 and a specificity of >0.96 during the
transcription procedure, the JECS had sufficient accuracy in
reporting CAs.
In the data accuracy report of the D-OR group, the Kochi
regional center enrolled a total of 7,140 infants. Of these, 168
(2.4%) reported CAs and 6,972 (97.6%) did not. In the reported
CA group, 152 (2.1%) were confirmed and 16 (0.2%) were not.
Because of the high number of non-reported CA infants, our
report could not provide an accuracy rate for non-reported infants.
However, other mistakable CAs diagnosis in respective medical
and insurance record were not found among non-confirmed cases.
This might suggest a risk of mistakes in using the transcription
forms. The number of transcription errors for non-reported CAs
infants was expected to be at least similar to the number of non-
confirmed CAs (16 cases). Using a sensitivity of >0.84 and a
specificity of >0.96, the number of transcription errors in cases
in the non-reported group was calculated to be 28 (sensitivity
0.84 and specificity 0.99). This number was more than expected.
Taking this into consideration, the JECS CA data can be
considered to have provided acceptable power for detecting the
impact of environmental factors on the CA occurrence. By
contrast, while D-OR had the highest number of CAs, it also had
the highest rate of misclassification. This misclassification would
be expected to cause an underestimation or an overestimation of
CA prevalence. eTable 2 provides evidence of overestimation
from the ICD-10 code. However, infants born in maternal homes
were not diagnosed with any CAs using the ICD-10 code because
midwives are not qualified to use the ICD-10 code in Japan.
For these reasons, the present authors recommend the use of
two different CA reporting groups in future analyses of CA
prevalence, for example, D-1M and D-OR.
In the medical termination of pregnancy and stillbirth groups,
a high proportion of life-threatening CAs and chromosomal
diseases were found. Schechtman et al reported a direct
correlation between CA severity and the rate of medical
termination of pregnancy rates.12 Furthermore, a study in Japan
showed that medical termination of pregnancy was performed in
93.3% of cases in which a chromosomal anomaly was confirmed
via prenatal conventional cytogenetic analysis at 15–18 weeks
of pregnancy.13 However, in the present report, life-threatening
CAs were also recorded in the spontaneous abortion group.
These comprised three cases of anencephaly, three cases of
gastroschisis, and one case of an omphalocele. Severe CAs were
also recorded in live births from the group with at delivery data
only. These included CLP, hydrocephaly, diaphragmatic hernia,
and esophageal atresia with or without fistula. Among the 44
cases for whom data were collected at 1 month of age only, two
CAs were recorded. These results suggest that JECS participants
with only a single data collection time-point (ie, at delivery only
or at 1 month only) may have a high CA risk. To account for
this, CA prevalence was determined using data collected both at
delivery and at 1 month.
To describe the CA data characteristics, we compared the CAs
in our previous study with those in other registrations. Previous
estimates of CP and CL=P prevalence per 10,000 births were 5.83
and 22.76, respectively, in the 2012 report of the Japanese
Association of Obstetricians and Gynecologists (JAOG)14; 5.88
and 8.26, respectively, in the 2011–2015 survey of the European
Surveillance of Congenital Anomalies (EUROCATS)15; and 6.35
and 10.63, respectively, in the 2004–2006 survey of the National
Birth Defects Prevention Network (NBDPN) in the United
States.16 CP prevalence in each of these three reports was similar
to, or slightly higher than, that found in the present report.
Compared to the present report, CL=P prevalence in EUROCATS
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and NBDPN were lower, while CL=P prevalence in JAOG was
higher. For spina bifida, the prevalence in the present analyses
was lower than the prevalence reported in JAOG (5.18) and
EUROCATS (5.11) and similar to or lower than the prevalence
reported in NBDPN (3.50).
These cross-study similarities and differences in the prevalence
of these major CAs are attributable to three factors. First, the
findings are influenced by selection bias. The research facilities
of the JAOG are mainly based at hospitals that provide care for
women with high-risk pregnancies, whereas the JECS collects
data from pregnant women who are managed in general hospitals
and maternity homes. Since spina bifida requires surgery
immediately after delivery, women with spina bifida pregnancies
are usually referred to tertiary centers.17 By contrast, surgery for
newborns with CP and CL=P is undertaken around 3–6 months
after delivery.18 In the Hokkaido study, prenatal diagnosis rates
for spina bifida were 100%, whereas they were approximately
81.8% and 92% for CP and CL=P.19 Moreover, between 2006
and 2016, 22 cases (31.0%) were referred after delivery to the
Yamaguchi University Hospital.20 This meant that CP and CL=P
newborns were mainly delivered at hospitals, as well as at
maternity homes. These differences led to higher prevalence rates
for spina bifida, CP, and CL=P in JAOG. Second, the cohorts
investigated in EUROCATS, NBDPN, and the present report
differed in terms of genetic factors. CL=P prevalence varies
according to race=ethnicity. Prevalence is lowest in American
blacks (5.8=10,000 live births), highest in American Indian or
Alaska Natives (14.3=10,000 live births), and intermediate in
other groups (whites, Hispanics, Asians, and Pacific Islanders).21
Moreover, non-syndromic CL=P has been associated with a
number of genetic mutations,22–24 and the frequency of single
nucleotide polymorphism risk variants for non-syndromic CL=P
differs according to race=ethnicity.25 By contrast, there are no
definite genetic risk factors for CP or spina bifida. EUROCATS
did not analyze race=ethnicity rates. However, the cohort covered
29% of births in Europe. Thus, the cohort may have been
multiethnic in nature. NBDPN involved American blacks,
American Indian or Alaska Natives, whites, Hispanics, Asians,
and Pacific Islanders. By contrast, the JECS cohort was almost
exclusively comprised of individuals from the Japanese
population. These genetic factors may partly explain the
difference in CL=P prevalence between the three reports. To
investigate these differences, genetic analyses of individuals
in the JECS cohort are warranted. Third, the three cohorts
showed differences in terms of environmental factors. Folic acid
deficiency is a well-known risk factor for spina bifida,26 and a
possible risk factor for CL=P but not for CP.27 Additional risk
factors for CL=P include smoking,27,28 alcohol,29 and drugs.30,31
Known risk factors for spina bifida include pre-gestational
diabetes,32 obesity,33 drugs,34 and pesticide exposure.35 However,
research has generated inconsistent findings for CA associations
with these risk factors, in particular environmental toxicants, and
most of the studies were conducted in Europe and the United
States. However, Europe, the United States, and Japan have
obvious geographic, nutritional, and cultural differences, and the
translation of findings from non-Asian countries to the Japanese
population is problematic. Further studies from JECS would
provide important data concerning the association between
environmental exposures and CAs in Asian countries.
Omphalocele prevalence in JAOG, EUROCATS, and NBDPN
was 2.22, 3.38, and 1.86, respectively, per 10,000 births. The
present finding of 26.6 per 10,000 pregnancies in D-1M was
therefore substantially higher than expected. This is attributable to
the Japanese terminology for this particular CA. ‘Saitai-hernia,’
which is the Japanese term for ‘omphalocele’, is easily confused
with ‘Sai-hernia,’ or ‘umbilical hernia.’ Umbilical hernia is a
common condition in infants, with a prevalence of 1.9–18.5% in
Caucasian populations.36 Thus, the occurrence in D-OR and D-
1M is not appropriate for the analysis of omphalocele prevalence.
The prevalence of congenital heart disease was also higher
in the present cohort than in EUROCAT. The prevalence in
EUROCATS was 76.46. In JECS, data on all forms of congenital
heart disease were collected under the broad category “congenital
heart disease.” This included low severities of congenital heart
disease, such as patent ductus arteriosus and patent foramen
ovale. By contrast, these low severity heart diseases were
excluded from EUROCATS. This might have resulted in the
higher prevalence of congenital heart disease in JECS. For future
investigations of specific congenital anomalies, such as tetralogy
of Fallot, JECS plans to access other databases, such as the
database of congenital heart disease in the information center for
specific pediatric chronic diseases in Japan.
JECS collected CA data at delivery and at 1 month of age, but
the protocol can result in unidentified CA cases being ignored.
For example, the Western Australian Birth Defects Registry
collected data from 3,294 CA cases born in 2000 and 2001. These
subjects had been diagnosed up to 6 years of age: 616 (18.7%)
were diagnosed prenatally, 1,574 (47.8%) by 1 month of age, 671
(20.4%) between 2 months and 11 months, and 400 (12.1%)
between 1 and 6 years of age.37 For comparison, the British Isles
Network of Congenital Anomaly Registers collected data for
5,911 CA cases born in 2012. These subjects had been diagnosed
up to 2 years of age: 3,074 (52%) were diagnosed prenatally,
1,291 (21.8%) after delivery until 1 month of age, and 835 (14%)
at an unknown time-point. After excluding cases for whom the
timing of diagnosis was unknown, 4,365 (86%) of cases were
diagnosed before 1 month of age.38 These reports showed an
increased rate of prenatal CA diagnosis as a result of prenatal
screening. In Japan, the guidance given to pregnant women at
regular health checks recommends testing by ultrasound at least
four times: twice before 23 weeks gestational age, once between
24 and 35 weeks, and once after 36 weeks. In the United
Kingdom and Australia, prenatal ultrasound screening is
performed twice, at around 12 and 20 weeks gestational age.
The CA detection rate of JECS was at least as high as that of the
United Kingdom in 2012. As expected, approximately 70–80% of
CAs cases in JECS were diagnosed before the age of 1 month.
The present report has three main strengths. First, JECS CA
data are based on reports from hospitals and maternity clinics
throughout Japan. Reporting bias was not considered, since data
collection was performed by research facility personnel rather
than by parents. Second, the rate of loss to follow-up was low
(2.2%). Third, CA prevalence was estimated on the basis of all
pregnancies in the cohort, including all cases of spontaneous
abortion and medical termination of pregnancy. Such data,
in particular those concerning spontaneous abortion, are not
recorded in other CA registries.15,16,37,38 However, these data are
important in terms of the identification of the environmental
causes of CAs.
The present report also had four limitations that warrant
mention. First, only the 61 CAs of interest were considered.
Second, misclassification may have occurred due to the
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mistranscription of medical records, which could have caused an
overestimation or underestimation of CA prevalence. Third, JECS
did not collect data from alternative sources, such as child health
systems or departments specializing in the diagnosis of CAs after
1 month of age. This is likely to have led to unidentified CA cases
being ignored after 1 month of age. To identify overlooked CA
cases, the JECS consortium plan to collect additional CA data on
2-year-old children receiving hospital treatment through the use of
parent-report questionnaires. Finally, methodological differences
between the JECS and other registries may have resulted in
the differing estimates of CA prevalence.39 Once the JECS data
become open access, the present authors recommend that two data
reporting groups, for example, D-1M and D-OR, are used for the
analysis of each CA. The number of omphalocele recorded at the 1
month data collection time-point may have been an overestimate,
due to misclassification secondary to the similar Japanese
terminology for omphalocele and umbilical hernia. Thus, for
omphalocele, D-DELIVERY or D-AND data should be used to
determine prevalence. There were some instances of misclassifi-
cation in the JECS data. Since JECS is not a population-based
registration program, the data cannot be used to generate definite
CA prevalence rates. However, the demographic characteristics
of the JECS pregnant women cohort are almost identical to those
reported in a previous national survey.7
Conclusions
The present report generated reliable data concerning the
prevalence of major CAs in the JECS cohort.
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APPENDIX B.
Members of the Japan Environment and Children’s Study (JECS),
as of 2017 (principal investigator, Toshihiro Kawamoto):
Hirohisa Saito (National Centre for Child Health and Develop-
ment, Tokyo, Japan), Reiko Kishi (Hokkaido Regional Center for
JECS, Hokkaido University, Sapporo, Japan), Nobuo Yaegashi
(Miyagi Regional Center for JECS, Tohoku University, Sendai,
Japan), Koichi Hashimoto (Fukushima Regional Center for JECS,
Fukushima Medical University, Fukushima, Japan), Chisato
Mori (Chiba Regional Center for JECS, Chiba University,
Chiba, Japan), Shuichi Ito (Kanagawa Regional Center for
JECS, Yokohama City University, Yokohama, Japan), Zentaro
Yamagata (Koshin Regional Center for JECS, University of
Yamanashi, Chuo, Japan), Hidekuni Inadera (Toyama Regional
Center for JECS, University of Toyama, Toyama, Japan),
Michihiro Kamijima (Aichi Regional Center for JECS, Nagoya
City University, Nagoya, Japan), Takeo Nakayama (Kyoto
Regional Center for JECS, Kyoto University, Kyoto, Japan),
Hiroyasu Iso (Osaka Regional Center for JECS, Osaka
University, Suita, Japan), Masayuki Shima (Hyogo Regional
Center for JECS, Hyogo College of Medicine, Nishinomiya,
Japan), Yasuaki Hirooka (Tottori Regional Center for JECS,
Tottori University, Yonago, Japan), Narufumi Suganuma (Kochi
Regional Center for JECS, Kochi University, Nankoku, Japan),
Koichi Kusuhara (Fukuoka Regional Center for JECS, University
of Occupational and Environmental Health, Kitakyushu, Japan),
and Takahiko Katoh (South Kyushu=Okinawa Regional Center
for JECS, Kumamoto University, Kumamoto, Japan).
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